{"id":"NCT03434275","sponsor":"Baudax Bio","briefTitle":"Evaluation of Preoperative N1539 in Total Knee Arthroplasty","officialTitle":"A Phase 3b, Randomized, Double-Blind, Placebo-Control, Multicenter, Evaluation of the Safety and Efficacy of N1539 Administered Preoperatively in Open Unilateral Total Knee Arthroplasty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-19","primaryCompletion":"2019-05-21","completion":"2019-05-21","firstPosted":"2018-02-15","resultsPosted":"2023-05-25","lastUpdate":"2023-05-25"},"enrollment":194,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain, Postoperative"],"interventions":[{"type":"DRUG","name":"N1539","otherNames":["Intravenous meloxicam"]},{"type":"DRUG","name":"Placebo","otherNames":["Intravenous placebo"]}],"arms":[{"label":"N1539 30 mg","type":"EXPERIMENTAL"},{"label":"IV Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to assess the effect of preoperative administration of N1539 on opioid consumption in subjects undergoing open unilateral total knee arthroplasty compared to placebo.","primaryOutcome":{"measure":"Opioid Use Hour 0-24","timeFrame":"Up to 24 Hours","effectByArm":[{"arm":"N1539 30 mg","deltaMin":18.94,"sd":1.32},{"arm":"IV Placebo","deltaMin":27.73,"sd":1.371}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["33502533"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":93},"commonTop":["Nausea","Vomiting","Hypotension","Pruritus","Constipation"]}}